FTC Eyes Disgorgement In Cephalon Pay-For-Delay Fight

The Federal Trade Commission told a Pennsylvania federal court Monday that the launch of generic versions of Cephalon Inc.'s Provigil did not moot its pay-for-delay suit against the drugmaker, because it...

Already a subscriber? Click here to view full article